New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For LLY;PFE;ACTC;CYTX;STEM;ATHX;LH;OVSC;NBS;PSTI;FLDM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
April 24, 2015
16:29 EDTLLYEli Lilly receives fourth FDA approval for CYRAMZA
Subscribe for More Information
09:37 EDTSTEMStemCells raises $25M in a public offering
Subscribe for More Information
09:20 EDTSTEMOn The Fly: Pre-market Movers
UP AFTER EARNINGS: eHealth (EHTH), up 24.7%... Starbucks (SBUX), up 4.2%... Microsoft (MSFT), up 5.2%... Google (GOOG, GOOGL), up 3.2% and up 3.7%, respectively... Amazon (AMZN), up 12% after reporting quarterly results and announcing shopping app for Apple Watch... Gigamon (GIMO), up 16.5%... Juniper Networks (JNPR), up 6.6%. ALSO HIGHER: Molycorp (MCP), up 10.2% following a Bloomberg report that China's export tax decision may boost rare earth demand... Mattel (MAT), up 4.4% after being upgraded to Buy from Neutral at Goldman... Innocoll (INNL), up 13.1% after 3.3M share Secondary priced at $9.00... Cytosorbents (CTSO), up 9.7% after CEO comments on CytoSorb in letter to shareholders. DOWN AFTER EARNINGS: Biogen (BIIB), down 4.7%... Altera (ALTR), down 1.7%... Pandora (P), down 4%... ResMed (RMD), down 8.7%... Xerox (XRX), down 4.7%... HomeAway (AWAY), down 3.6% after reporting quarterly results and departure of officers. ALSO LOWER: Ubiquiti (UBNT), down 14.4% following CFO resignation and preliminary third quarter results... 3D Systems (DDD), down 10.4% after reporting preliminary first quarter results... StemCells (STEM), down 23.2% after filing to sell common stock... Aerie Pharmaceuticals (AERI), down 54.7% after Rhopressa Phase 3 trial did not meet primary endpoint.
April 23, 2015
19:16 EDTSTEMOn The Fly: After Hours Movers
Subscribe for More Information
16:38 EDTSTEMStemCells files to sell common stock, warrants, no amount given
Maxim Group LLC is acting as sole book-running manager for the offering.
09:52 EDTLLYEli Lilly sees at least $200M in savings from Novartis Animal Health acquisition
09:33 EDTLLYEli Lilly sees stronger doller hurting FY15 revenue by 7.5%
Subscribe for More Information
09:18 EDTCYTXOn The Fly: Pre-market Movers
Subscribe for More Information
08:15 EDTCYTXCytori reports preclinical data on use of cell therapy in burn/radiation wounds
Subscribe for More Information
06:27 EDTLLYEli Lilly backs FY15 adjusted EPS view of $3.10-$3.20, consensus $3.15
Subscribe for More Information
06:26 EDTLLYEli Lilly reports Q1 EPS 87c, consensus 77c
Subscribe for More Information
April 22, 2015
15:50 EDTLLYNotable companies reporting before tomorrow's open
Subscribe for More Information
14:35 EDTLLYEarnings Watch: Lilly to report Q1 results amid patent expirations
Eli Lilly and Company (LLY) is scheduled to report first quarter earnings before the market open on Thursday, April 23 with a conference call scheduled for 9:00 am ET. Lilly is a global pharmaceutical manufacturer that also has an animal health business segment. EXPECTATIONS: Analysts are looking for earnings per share of 77c on revenue of $4.62B, according to First Call. The consensus range for EPS is 64c-99c on revenue of $4.54B-$4.7B. LAST QUARTER: Eli Lilly reported fourth quarter EPS of 75c, compared to consensus estimates of 74c, on revenue of $5.12B against estimates of $5.2B. The company said it sees fiscal year 2015 EPS of $3.10-$3.20 on revenue of $19.5B-$20B. Lilly's CEO John Lechleiter commented on the quarter, "While Lilly's fourth quarter 2014 results continue to reflect the impact of patent expirations, we are moving to a period of growth led by diabetes, oncology and animal health. Despite the loss of significant revenue for Cymbalta and Evista following the expiration of our U.S. patents, we saw strong performance from many other products. At the same time, we made excellent progress with our innovation-based strategy, and we continue to advance our pipeline." STREET RESEARCH: On March 25, Suntrust raised its price target on Lilly shares to $95 from $80. After meeting with Eli Lilly's management, SunTrust said it expects the company's oncology and diabetes sales to double over the next five years. The firm is upbeat about the short-term outlook of the company's diabetes treatment, and says that its late stage autoimmune, Alzheimer's and cardiovascular treatments are advancing, while its Alzheimer's programs remain underappreciated. SunTrust said it expects the company's earnings CAGR to be in the mid teens between 2015-2020. It kept a Buy rating on Lilly shares. PRICE ACTION: Lilly shares are relatively flat since the company's last earnings report on January 30, and are trading up fractionally to $72.40 in midday trading ahead of Thursday's earnings release.
05:48 EDTATHXStocks with implied volatility movement; CSX ATHX
Stocks with implied volatility movement; CSX (CSX) 40, Athersys (ATHX) 151 according to iVolatility.
April 21, 2015
10:01 EDTPFEPfizer receives FDA breakthrough therapy designation for Xalkori
Subscribe for More Information
09:45 EDTATHXMaxim still bullish on Athersys, says data show 'strong signal'
Maxim analyst Jason Kolbert told investors today that he remains bullish on Athersys after the company announced Friday morning its stroke trial missed the primary and secondary endpoints. Kolbert says the data show MultiStem appears to be able to extend the treatment window in stroke from a few hours to 36 hours, which he calls "dramatic." He views the data as showing a "strong signal," and added "it seems that no one wants to hear or look" at it. The analyst expects Athersys to announce plans to move forward in a Phase IIb/III global trial in the U.S., Europe and Japan. He pointed out that Maxim hopes to announce next week a series of conference calls with Athersys management and experts. Kolbert kept a Buy rating on Athersys with a $9 price target. The stock is trading down 3c to $1.32 in early trading.
08:18 EDTPFEPain Therapeutics resumes responsibility for Remoxy
Subscribe for More Information
08:14 EDTLHQuest Diagnostics and Inserm launch BRCA Share initiative
Quest Diagnostics (DGX) and Inserm, the French National Institute of Health and Medical Research institution, launched BRCA Share, a novel datashare initiative they co-founded to provide scientists and laboratory organizations around the world with open access to BRCA1 and BRCA2 genetic data. The program's goal is to accelerate research on BRCA gene mutations, particularly variants of uncertain significance, to improve the ability of clinical laboratory diagnostics to predict which individuals are at risk of developing hereditary breast and ovarian cancers. Laboratory Corporation of America Holdings (LH) is the first participant in the initiative, which is structured as a user group. B
08:06 EDTPFEPfizer says Phase 3 inotuzumab ozogamicin study met first primary endpoint
Subscribe for More Information
06:40 EDTLHStart-up to offer saliva test for breast cancer susceptibility, NY Times says
Subscribe for More Information
April 20, 2015
11:53 EDTATHXPiper Jaffray biotech analysts hold an analyst/industry conference call
Biotech Analysts Tenthoff and Adler, along with Dr. Stanley Tuhrim, discuss Athersys' MultiStem ischemic stroke results on an Analyst/Industry conference call to be held on April 20 at 1 pm.
09:20 EDTLLYLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
09:01 EDTLLYEli Lilly to present early stage data from several targeted cancer therapies
Subscribe for More Information
08:08 EDTLLYEli Lilly announces positive results from ixekizumab study
Eli Lilly and Company announced that the investigational medicine ixekizumab was statistically superior to placebo in the treatment of patients with active psoriatic arthritis, or PsA, as demonstrated by the proportion of patients achieving an ACR 20 response. ACR 20 is a standard assessment that represents a 20% reduction in disease signs and symptoms as defined by the American College of Rheumatology response criteria. During the 24-week, Phase 3 study, titled SPIRIT-P1, patients who were na´ve to biologic disease-modifying antirheumatic drugs were treated with one of two different ixekizumab dosing regimens or placebo.
08:02 EDTPFEMerck KGaA, Pfizer initiate Phase III study with Avelumab
Subscribe for More Information
07:32 EDTNBSNeoStem announces expanded cell therapy relationship with Kite Pharma
Subscribe for More Information
07:20 EDTLLYAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
06:05 EDTPFEProvectus receives notice of allowance for PV-10 combined with other drugs
Subscribe for More Information
05:18 EDTPSTIPluristem prepares Phase II clinical trials for CLI in EU, Japan
Subscribe for More Information
April 17, 2015
12:21 EDTATHXOn The Fly: Top stock stories at midday
Subscribe for More Information
11:04 EDTATHXAthersys data provide 'glimmer of activity,' says Piper Jaffray
Subscribe for More Information
10:07 EDTATHXHigh option volume stocks
Subscribe for More Information
09:14 EDTATHXOn The Fly: Pre-market Movers
Subscribe for More Information
06:27 EDTATHXAthersys says MultiStem missed primary, secondary endpoints
Subscribe for More Information
05:56 EDTATHXStocks with implied volatility above IV index mean; ATHX GMCR
Stocks with implied volatility above IV index mean; Athersys (ATHX) 415, Keurig Green Mountain (GMCR) 52 according to iVolatility.
April 16, 2015
12:16 EDTLLYEli Lilly and Bristol-Myers restructure Erbitux collaboration in N. America
Subscribe for More Information
11:09 EDTATHXAthersys upcoming data could take shares to 45c, says Piper Jaffray
Subscribe for More Information
08:13 EDTSTEMStemCells completes enrollment in first cohort of Phase II Pathway Study
StemCells announced that it has completed transplanting the six patients comprising the first cohort of its Phase II Pathway Study. The first cohort is an open-label dose escalation arm to determine the cell dose to be used for the second cohort of the study. The second cohort of the study is a single-blind arm in 40 patients that will assess efficacy of the company's proprietary HuCNS-SC platform technology for the treatment of cervical spinal cord injury.
07:16 EDTATHXAthersys volatility elevated into Phase 2 ischemic stroke trial results
Athersys April call option implied volatility is at 408, May is at 390, July is at 230, October is at 204; compared to its 26-week average of 161 according to Track Data, suggesting large price movement into Phase 2 ischemic stroke trial results to be presented at ESOC.
05:59 EDTATHXStocks with implied volatility above IV index mean; ATHX GMCR
Stocks with implied volatility above IV index mean; Athersys (ATHX) 390, Keurig Green Mountain (GMCR) 53 according to iVolatility.
April 15, 2015
08:04 EDTPFEPfizer: PALOMA-3 trial for IBRANCE met primary endpoint, trial stopped early
Subscribe for More Information
07:41 EDTLLYEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
06:07 EDTATHXStocks with implied volatility above IV index mean; ATHX WETF
Subscribe for More Information
April 13, 2015
15:12 EDTPFEMylan enters settlement, license agreement with Pfizer regarding Viagra
Mylan (MYL) announced that its subsidiaries Mylan Inc. and Mylan Pharmaceuticals have entered into a settlement and license agreement with Pfizer (PFE), Pfizer Limited and Pfizer Ireland Pharmaceuticals to settle patent litigation relating to Mylan's Abbreviated New Drug Application filed with the U.S. FDA for Sildenafil Citrate Tablets 25 mg, 50 mg, and 100 mg. This product is the generic version of Viagra, which is indicated to treat erectile dysfunction. Under the terms of the agreement, Mylan will be able to launch its ANDA products pursuant to a royalty-bearing license as early as December 11, 2017, or sooner under certain conditions, subject to FDA approval. All other terms and conditions of the settlement and license agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission. For the 12 months ending Dec. 31, 2014, Viagra had U.S. sales of approximately $1.3B, according to IMS Health.
08:03 EDTCYTXCytori provides twelve month data update on Scleradec-I trial
Subscribe for More Information
07:38 EDTATHXAthersys volatility elevated into Phase 2 ischemic stroke trial results
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use